When does Rinvoq patent exclusivity end?
Rinvoq's U.S. compound patent is set to expire on December 20, 2033 [1]. This date marks the end of its primary patent protection in the United States.
What happens when Rinvoq's patent expires?
Following the expiration of Rinvoq's compound patent, generic versions of the drug may become available. This typically leads to a significant decrease in the drug's price due to market competition [2].
Can biosimilars be developed for Rinvoq?
Rinvoq is a small molecule drug, not a biologic. Therefore, biosimilars, which are highly similar versions of biologic medicines, cannot be developed for it. Instead, generic versions of small molecule drugs can be produced [3].
Who makes Rinvoq?
Rinvoq is manufactured by AbbVie [1].
What is Rinvoq used for?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor approved for the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease [4].
What are the potential risks associated with Rinvoq?
Like other JAK inhibitors, Rinvoq carries a boxed warning regarding serious infections, increased risk of death in certain patients aged 50 and older with cardiovascular risk factors treated with a JAK inhibitor plus a brute phosphodiesterase 4 inhibitor, cancer, blood clots, heart attack, stroke, and other cardiovascular events [4].
How does Rinvoq compare to other treatments?
Rinvoq is a targeted therapy that works by inhibiting specific Janus kinase enzymes involved in the inflammatory process. It offers an alternative to other immunosuppressants and biologic agents used for similar autoimmune and inflammatory conditions [4].
Are there any ongoing patent disputes for Rinvoq?
Information regarding specific ongoing patent disputes for Rinvoq is not provided in the available data. However, patent challenges are common for branded drugs nearing the end of their exclusivity periods [5].
Where can I find more information on drug patents?
For detailed information on drug patents, including expiration dates and patent landscapes for various medications, resources such as DrugPatentWatch.com are available [1].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Rinvoq Patent Expiration. Retrieved from https://drugpatentwatch.com/
[2] U.S. Food and Drug Administration. (n.d.). Generic Drugs: Questions and Answers.
[3] U.S. Food and Drug Administration. (n.d.). Biosimilar User Fee Act (BSUFA).
[4] AbbVie Inc. (n.d.). Rinvoq (upadacitinib) Prescribing Information.
[5] U.S. Food and Drug Administration. (n.d.). Understanding the Approval of Generic Drugs.